Novavax (NVAX) Misses Q4 EPS by 99c ; Offers Guidance

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($1.44), $0.99 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $291 million versus the consensus estimate of $321.97 million.

GUIDANCE:

Novavax sees FY2024 revenue of $0.8-1 billion, versus the consensus of $0.97 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Qtrex Quantum executives plan to buy up to 2M shares over 12 months
• Playboy to buy back 16.6M shares from Fortress at $1.05 each